{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:05:47Z","timestamp":1790067947410,"version":"4.0.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease, is the most prevalent chronic liver disorder globally and is tightly linked to obesity, diabetes, dyslipidemia, and metabolic syndrome. MASLD spans a continuum from simple steatosis to metabolic dysfunction\u2013associated steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Its pathogenesis is driven by complex interactions among host genetics, metabolic stress, dietary factors, gut microbiota dysbiosis, immune dysregulation, and oxidative injury. The gut\u2013liver axis plays a central role, with microbial metabolites and altered intestinal permeability driving hepatic inflammation and fibrogenesis. Genetic variants, including PNPLA3, TM6SF2, and MBOAT7, modulate disease susceptibility and metabolic pathways. Emerging therapies target interconnected mechanisms through lifestyle interventions, microbiome-directed strategies, bile acid signaling, incretin-based treatments, and antifibrotic approaches. Advances in omics technologies and biomarkers support precision medicine frameworks. Despite major advances in mechanistic understanding, resmetirom has recently become the first FDA-approved therapy for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis. Nevertheless, effective treatment options remain limited, emphasizing the need for additional mechanism-based and personalized therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fgstr.2026.1824548","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:50:17Z","timestamp":1790067017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MASLD beyond the liver: decoding the gut\u2013genetic\u2013metabolic nexus"],"prefix":"10.3389","volume":"5","author":[{"given":"Philippe","family":"Attieh","sequence":"first","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nassif","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Maghzal","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bedran","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Kassas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Sahyoun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand","place":["Al-Koura, Tripoli, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on NAFLD: Focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.35511","article-title":"New-onset age of nonalcoholic fatty liver disease and cancer risk","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HEP.0000000000000412","article-title":"A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD","volume":"78","year":"2023","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060824","article-title":"NAFLD: Mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"key":"B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186423","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease and the gut microbiome: Pathogenic insights and therapeutic innovations","volume":"135","author":"Schnabl","year":"2025","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104816","article-title":"Host-bacterial mutualism in the human intestine","volume":"307","author":"B\u00e4ckhed","year":"2005","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1575770","article-title":"Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver","volume":"16","author":"Cebi","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: The role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46070381","article-title":"The role of microbiota-related co-metabolites in MASLD progression: A narrative review","volume":"46","author":"Martin-Grau","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13121532","article-title":"Interplay of oxidative stress, gut microbiota, and nicotine in metabolic-associated steatotic liver disease (MASLD)","volume":"13","author":"Mignini","year":"2024","journal-title":"Antioxidants"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","article-title":"The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux","volume":"126","author":"Samuel","year":"2016","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.11.023","article-title":"Apelin and the gut microbiome: Potential interaction in human MASLD","volume":"56","author":"Effenberger","year":"2024","journal-title":"Dig Liver Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40168-024-02004-7","article-title":"Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: Links with disease severity and metabolic dysfunction parameters","volume":"13","author":"Schwenger","year":"2025","journal-title":"Microbiome"},{"key":"B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jgh.16750","article-title":"Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction\u2010associated steatotic liver disease: A comprehensive review","volume":"40","author":"Ku","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2025","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12944-025-02474-0","article-title":"Hypothyroidism\/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: Advances in mechanism and treatment","volume":"24","author":"Pu","year":"2025","journal-title":"Lipids Health Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","article-title":"Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids","volume":"82","author":"Zhang","year":"2025","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000310","article-title":"Gut microbiota and metabolic biomarkers in metabolic dysfunction\u2013associated steatotic liver disease","volume":"8","author":"Long","year":"2024","journal-title":"Hepatol Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.1038\/s41598-024-59605-3","article-title":"Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Ren","year":"2024","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1502151","article-title":"Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease","volume":"11","author":"Wang","year":"2024","journal-title":"Front Nutr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1573636","article-title":"Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: The mediating roles of inflammation and body mass index","volume":"12","author":"Pu","year":"2025","journal-title":"Front Nutr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312809","article-title":"Metabolomic hallmarks of obesity and metabolic dysfunction-associated steatotic liver disease","volume":"25","author":"Beyo\u011flu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40842-024-00187-4","article-title":"From adiposity to steatosis: Metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome \u2013 current insights and future directions","volume":"10","author":"Basil","year":"2024","journal-title":"Clin Diabetes Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1543003","article-title":"Unraveling the link between metabolic dysfunction-associated steatotic liver disease and osteoporosis: A bridging function of gut microbiota","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2478\/rjim-2024-0004","article-title":"The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial","volume":"62","author":"Mitrovi\u0107","year":"2024","journal-title":"Rom J Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1600439","article-title":"Gut microbiota modulation by Traditional Chinese Medicine: A translational strategy for metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/livers5010011","article-title":"Gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): Emerging pathogenic mechanisms and therapeutic implications","volume":"5","author":"Abdelhameed","year":"2025","journal-title":"Livers"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tem.2024.04.021","article-title":"Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases","volume":"36","author":"Vazquez-Uribe","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102397","article-title":"Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61020192","article-title":"Effects of selected food additives on the gut microbiome and metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"61","author":"Jarmakiewicz-Czaja","year":"2025","journal-title":"Med (Mex)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12951-025-03228-x","article-title":"Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota","volume":"23","author":"Dong","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B38","first-page":"402","article-title":"Engineered Escherichia coli Nissle 1917 expressing IGF1 and FGF19 reduce liver fat accumulation and restore microbial equilibrium in a metabolic dysfunction-associated steatotic liver disease mice model","volume-title":"Proceedings","author":"Lok","year":"2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/s41467-023-39028-w","article-title":"Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae","volume":"14","author":"Gan","year":"2023","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.cell.2022.03.015","article-title":"Cell surface fluctuations regulate early embryonic lineage sorting","volume":"185","author":"Yanagida","year":"2022","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05699-z","article-title":"Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: A meta-analysis","volume":"64","author":"Liu","year":"2019","journal-title":"Dig Dis Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Saeed","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088290","article-title":"Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Grefhorst","year":"2025","journal-title":"BMJ Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101363","article-title":"Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD","volume":"7","author":"Moolla","year":"2025","journal-title":"JHEP Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000484","article-title":"Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment","volume":"8","author":"Zhang","year":"2024","journal-title":"Hepatol Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.990953","article-title":"Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"103702","DOI":"10.1016\/j.numecd.2024.07.019","article-title":"Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future","volume":"35","author":"Corrao","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051260","article-title":"Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: From steatosis to hepatocellular carcinoma","volume":"13","author":"Jee","year":"2025","journal-title":"Biomedicines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1569915","article-title":"The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s40001-024-02072-3","article-title":"Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances","volume":"29","author":"Kumar","year":"2024","journal-title":"Eur J Med Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12876-025-03732-2","article-title":"Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database","volume":"25","author":"Du","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s41043-024-00618-z","article-title":"Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission","volume":"43","author":"Lin","year":"2024","journal-title":"J Health Popul Nutr"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1824548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:50:18Z","timestamp":1790067018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1824548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":53,"alternative-id":["10.3389\/fgstr.2026.1824548"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1824548","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1824548"}}